20 categories

Compounds

One subcategory per compound family. Pharmacology, published data, practical experience, and the maintained reference page for each.

207 topics10,207 posts73 solved Moderators: hana.sato, j.mwangi About this category

Semaglutide 35 Tirzepatide 30 Retatrutide 26 Cagrilintide & amylin analogues 24 Oral incretins 24 Secretagogues & GH axis 24 Repair & healing peptides 22 Other compounds 22

207 topics · page 4 of 7

Topic	Participants	Replies	Views	Activity
Dose numbers for oral formulations are not comparable to injectable ones Compounds › Oral incretins orforglipron PIONEER programme SOUL trial On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+19	23	39k	6mo
Why oral semaglutide needs an absorption enhancer at all Compounds › Oral incretins randomised trial orforglipron oral semaglutide SOUL trial Solved Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…	+59	65	61k	7mo
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Compounds › Oral incretins oral semaglutide randomised trial PIONEER programme SOUL trial Solved Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…	+130	135	11k	7mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…	+12	16	11k	7mo
CJC-1295 with and without DAC: what the modification does — what changed since Compounds › Secretagogues & GH axis GHRP class observational data CJC-1295 tesamorelin CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…		4	5.1k	7mo
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
How to read a phase 2 result without treating it as a phase 3 result Compounds › Retatrutide randomised trial preprint effect size TRIUMPH programme The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…	+36	40	35k	7mo
Reading SURMOUNT-1 without the press release Compounds › Tirzepatide SURMOUNT programme effect size randomised trial SURPASS programme Posting this under the heading it deserves: Reading SURMOUNT-1 without the press release Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA , 2024) cited in support of a claim I do not…	+103	121	7k	7mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial Wiki On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…	+2	6	2.4k	7mo
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? Compounds › Cagrilintide & amylin analogues cagrisema randomised trial cagrilintide amylin analogues Closed Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 (…	+21	25	45k	7mo
Why tirzepatide titration schedules have more steps than semaglutide's Compounds › Tirzepatide SURMOUNT programme SURPASS programme randomised trial tirzepatide Solved Wiki Asking directly, because I could not find a straight answer: Why tirzepatide titration schedules have more steps than semaglutide's Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…		4	8.4k	7mo
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med ,…	+85	90	13k	7mo
Tirzepatide's shorter half-life and its one practical consequence Compounds › Tirzepatide SURPASS programme randomised trial effect size tirzepatide Wiki On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+18	29	20k	8mo
Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since Compounds › Semaglutide semaglutide SELECT trial type 2 diabetes STEP programme Semaglutide and gastric emptying — the mechanism behind most of the side-effect profile — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA ,…	+6	10	6.1k	8mo
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-4 ( JAMA ,…	+19	23	332	8mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Compounds › Tirzepatide SURMOUNT programme tirzepatide randomised trial effect size Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. I have seen SCALE ( N Engl J Med , 2015) cited in support…	+4	8	14k	8mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please…	+100	108	1.3k	8mo
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Compounds › Tirzepatide tirzepatide SURPASS programme effect size randomised trial Closed Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med ,…	+89	101	32k	8mo
Reading a supplier's product description as a marketing document Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim I…	+86	97	62k	8mo
Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Comparing PIONEER 6 ( N Engl J Med , 2019) with STEP 8 (…	+18	22	37k	8mo
[2026 update] Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting; the…	+58	63	40k	9mo
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide STEP programme SELECT trial randomised trial type 2 diabetes Under review On the subject in the title: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a…	+72	81	1.5k	9mo
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Compounds › Tirzepatide SURMOUNT programme randomised trial tirzepatide SURPASS programme Solved Closed Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med…	+122	136	48k	9mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Solved Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version Comparing PIONEER 6 ( N Engl J Med ,…	+48	52	609	10mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Compounds this community declines to help with, and why Compounds › Other compounds research use only needs a source mislabelling custom synthesis Solved Wiki Compounds this community declines to help with, and why — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SCALE ( N Engl J Med , 2015) and…	+81	87	35k	10mo
Why catalogue breadth is not evidence of anything — what changed since Compounds › Other compounds custom synthesis mislabelling needs a source research use only Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…	+62	66	26k	10mo
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP…		2	3.8k	10mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo